Santen Pharmaceutical Co., Ltd. (OTCMKTS:SNPHY) Short Interest Up 32.5% in February

Santen Pharmaceutical Co., Ltd. (OTCMKTS:SNPHY) was the target of a large growth in short interest in February. As of February 15th, there was short interest totalling 11,000 shares, a growth of 32.5% from the January 31st total of 8,300 shares. Based on an average trading volume of 17,500 shares, the days-to-cover ratio is presently 0.6 days.

Santen Pharmaceutical Stock Performance

SNPHY opened at $9.62 on Thursday. Santen Pharmaceutical has a 12 month low of $8.65 and a 12 month high of $13.00. The company has a fifty day simple moving average of $9.72 and a 200 day simple moving average of $10.99.

Santen Pharmaceutical Company Profile

Santen Pharmaceutical Co, Ltd. engages in the research and development, manufacture, and marketing of pharmaceuticals and medical devices in Japan and internationally. Its product portfolio includes tafluprost/timolol maleate, a prostaglandin F2a derivative and a beta-adrenergic receptor blocker; and netarsudil mesilate and latanoprost, a prostaglandin F2a derivative which is marketing approval phase for the treatment of glaucoma and ocular hypertension.